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Abstract: Many drugs may cause toxic injury to the lungs and the pleura. Cabergoline is an ergoline derivative which has 
been used in Spain for seven years to control symptoms of Parkinson’s disease. We report a patient with dyspnea, bilateral 
pleural effusion and distal swelling. After a series of complementary tests (blood analysis, chest CT, echocardiogram, 
pleural tap, pleural biopsy), etiological screening ruled out infection, malignancy or inflammation. Given the patient’s 
history of three years’ treatment with cabergoline, the drug was considered a possible cause and was progressively 
withdrawn. The patient’s clinical condition improved and radiological images were disease-free. Using Karch and 
Lasagna’s classical criteria, we defined a relationship of “probable causality” between the drug and the adverse effects 
reported. 
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INTRODUCTION 
  Today, more than 350 drugs are known to produce 
pleuro-pulmonary damage [1]. The diagnosis of drug-
induced pulmonary disease is usually per exclusionem since 
in most cases there is no specific diagnostic test [1]. If 
disease is suspected, Karch and Lasagna’s classical criteria 
are applied to try to establish causal relations [2]. We report 
a patient who developed pleuro-pulmonary pathology, 
mainly in the form of pleural effusion, after prolonged 
administration of cabergoline. 
CASE REPORT 
  Sixty-five year-old male, ex-smoker with an accumulated 
dose of 40 packs-year and without any work-related history 
of interest. He had undergone surgery for colon cancer and 
was currently disease-free. He had Parkinson’s disease of 
more than 10 years’ evolution and had been receiving L-
Dopa (1600mg/d) combined with carbidopa (250mg/d) and 
benserazide (150mg/d) since the diagnosis, entacapone 
(800mg/d) and cabergoline 4mg/d (the latter added three 
years previously). He was referred to our unit for progressive 
dyspnea, swollen ankles and intolerance of the supine 
position for over a month. The only finding of interest in the 
physical examination was the presence of bilateral basal 
hypophonesis in the respiratory auscultation, regular heart 
rhythm without murmurs and pitting edemas in the lower 
half of both legs. Blood analysis: ESR 70, LDH 333, CRP 
1.3, PSA, Reumatoid factor and anti-tissue antibodies   
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were within reference values. Chest x-ray: bilateral pleural 
effusion (Fig. 1). Electrocardiogram: sinus rhythm 75 per 
minute, without repolarization disturbance. Echocardiogram: 
alteration in ventricular relaxation with a left ventricle 
ejection fraction of 60% without valvulopathy and preserved 
global contractility. Initially, heart failure was considered; 
diuretic treatment was initiated, but only achieved a slight 
improvement in the distal swelling. Diagnostic pleural tap 
was compatible with a lymphocyte exudate with low ADA 
value (Table 1); cytological and microbiological studies 
(Ziehl-Neelsen stain and Lowenstein-Jensen culture) were 
negative. Pleural biopsy showed marked fibrosis and isolated 
areas of reactive mesothelial proliferation without evidence 
of malignancy. Chest CT showed bilateral pleural thickening 
and effusion affecting the underlying parenchyma (Fig. 2). 
Respiratory function testing: FVC 2.88L (73%), FEV1 2.18L 
(77%), FEV1/FVC 76% (bronchodilator test was non-
significant), TLC 4.55L (73%), RV 1.60L (76%), DLCO 
71%, KCO 84%. Arterial blood gas analysis on room air: pH 
7.43, PaO2 88.7 mmHg, PaCO2 36.7 mmHg, bicarbonates 
25.3 mEq/L, Alveolo-arterial gradient 14 mmHg, COHb 
0.4%. Due to the poor clinical response to diuretic treatment 
and after ruling out other possible causes of the symptoms 
(infection, malignancy, systemic disease, renal failure) a 
pharmacological etiology was considered possible, and so 
carbegoline treatment was withdrawn (after agreeing on a 
new therapeutic approach with the neurology service). After 
two years of clinical and radiological follow-up, the patient 
had clinically improved, mild left pleural thickening persists 
(Fig. 3) and the pulmonary function testing shows a relative 
improvement of the restriction pattern (FVC 2.94L (75%), 
FEV1 2.16L (76%), FEV1/FVC 74%, TLC 4.57L (73%), 
RV 1.58L (73%), DLCO 70%, KCO 78%). Pleuropulmonary Toxicity of Another Anti-Parkinson’s Drug  The Open Respiratory Medicine Journal, 2009, Volume 3    91 
 
Fig. (1). Chest x-ray at the beginning of the study. Observe the 
pleural effusion affecting both hemithoraces. 
(A) 
 
(B) 
 
Fig. (2). (A: Mediastinal window and B: parenchymal window). CT 
Scan at the beginning. Observe the pleural effusion affecting both 
hemithoraces. Parenchymal lung opacities are also seen. 
(A) 
 
(B) 
 
Fig. (3). (A: Mediastinal window and B: parenchymal window) CT 
scan at the end of follow-up. Observe the improvement in the 
pleuro-pulmonary abnormalities compared with the previous chest 
CT scan. The pleural effusion has disappeared, but pleural fibrosis 
remains to some extent. 
Table 1.  Characteristics of Patient’s Pleural Fluid 
 
  Cellularity: 750 leukocytes per mm
3, 
 95%  lymphocytes, 
  5% neutrophils;  
  Ratio Proteins in Pleural Fluid/Blood (g/L): 51/ 79= 0.65 
  Ratio LDH in Pleural Fluid/Blood (U/L) 560/ 333 = 1.68 
  ADA: 15.2 U/L 
 
DISCUSSION 
  Drug-induced pleural effusion is less frequent than drug-
induced parenchymal lung disease, though the two 
conditions may co-occur [1]. Some thirty substances are 
known to be possible causes of pleural effusion, among 
which the most frequent are: cardiovascular drugs 
(propranolol, amiodarone), ergoline derivatives (methy-
sergide, bromocriptine), chemotherapy drugs (bleomycin, 
mitomycin, procarbazine, methotrexate, cyclophosphamide), 92    The Open Respiratory Medicine Journal, 2009, Volume 3  Belmonte et al. 
antibiotics such as nitrofurantoin and the sclerotherapeutic 
agents sodium morrhuate and absolute alcohol [1, 2]. 
  Cabergoline is an ergoline derivative with potent 
dopamine agonist properties. It was approved by the Food 
and Drug Administration (FDA) in 1997 and has been 
marketed in Spain since 2001 for the treatment of signs and 
symptoms associated with Parkinson’s disease [3]. The 
incidence of pleuro-pulmonary damage due to cabergoline is 
estimated to be between 2 and 6% [1, 4]. 
 The  mechanism  via which ergoline derivatives produce 
fibrosis (either pleuropulmonary, retroperitoneal or cardiac) 
seems to be related to their serotoninergic effect, acting as 5-
HT2b receptor agonists [5]. This leads to the activation of 
cellular mitogenesis (fibroblasts) inducing fibrosis in the 
organ affected (for instance, the cardiac valve, the pleura and 
so on) [5, 6-10]. 
  The clinical presentation of drug-induced pleural effusion 
varies from asymptomatic forms to acute pleuritis [1], dry 
cough, dyspnea and distal swelling [4]. Chest X-ray shows 
the presence of uni- or bilateral pleural effusion with or 
without pulmonary infiltrates [4]. The biochemical analysis 
of pleural effusion usually corresponds to an exudate of 
lymphocytes and/or eosinophils with low ADA [1, 4]. Our 
patient presented all these features. Cases of constrictive 
pericarditis [11] and cardiac valve regurgitation [3] have also 
been reported. The time between the initiation of treatment 
and appearance of symptoms ranges between 5 and 48 
months (Table 2); in our case, the clinical symptoms 
appeared after 3 years of treatment 
  Withdrawal of the drug leads to an improvement – on 
occasions, resolution of the pleural effusion – though the 
fibrotic changes in the pleura and parenchyma may persist 
[1, 4]. Treatment with systemic corticoids reduces the pleural 
thickening and the pulmonary interstitial involvement 
although not all the patients have been treated with oral 
corticosteroids (Table 2). Our patient improved with the 
withdrawal of the drug though oral corticoids were added 
(prednisolone at doses of  mg /Kg weight in decreasing 
doses over 4 months) but some pleural thickening and 
parenchimal fibrotic damage remained. Our case meets four 
of Karch and Lasagna’s five criteria [6, 19]. The fifth 
criterion (reintroduction of the drug to test side effects) could 
not be confirmed. Since the side effect was already known, it 
was not considered ethical to reinitiate the drug treatment 
after the clinical improvement. In the case of a pleural 
effusion with a lymphocyte exudate, any drug being 
administered as treatment should be considered a possible 
cause before a more exhaustive study is carried out which 
may incur unnecessary economic cost and discomfort to the 
patient [1]. 
  For all these reasons, we agree with the authors who 
recommend radiology and a pulmonary function study prior 
to the start of treatment with an ergoline derivative, and 
subsequent active monitoring of pleuropulmonary toxicity. 
We also recommend follow-up studies of this potential side 
effect after a minimum of 6-12 months of treatment. 
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ABBREVIATIONS 
ADA =  Adenosine  Deaminase 
COHb =  Carboxyhemoglobine 
Chest CT  =  Chest Computed Tomography 
CRP =  C-Reactive  Protein 
DLCO  =  Diffusing Lung capacity for carbon  
     monoxide 
ESR =  Erythrocyte  Sedimentation  Rate 
FEV1  =  Forced Espiratory Volum in the 1st minute 
FVC =  Forced  Vital  Capacity 
KCO =  Corrected  DLCO 
LDH =  Lactate  Dehydrogenase 
Table 2.  Review of the Literature 
 
Reference  Cabergoline 
Dose 
Cabergoline’s 
Treatment Duration 
Length of Respiratory 
Symptoms 
Adverse Effect  Treatment with 
Oral Steroids 
Villavicencio [2]  1mg/day  Four months  Three months  
Pleural efusión 
Intersticial lung diasease 
Pericardial thickening 
No 
Bhatt MH [12]   3mg/day  *  One month  Pleuropulmonary disease   No 
Frans E [13]  *  Ten months  Three months  Pleuropulmonary disease  No 
Ling LH [14]  10mg/day  Two years  8-10 weeks  Pleuropulmonary inflammatory-fibrotic 
syndrome 
No 
Frank W [15]  1mg/day  Four months  4-8 weeks  Intersticial pneumonitis  No 
Townsend M [16]  5mg/day  Six years  Three months  Constrictive pericarditis 
Pleural effusion 
Yes 
Guptha SH [17]  4mg/day  Four years  Four months  Pleural thickening 
Pleural effusion 
No 
Hashiguchi S [18]  3mg/day  Six years  Three months  Pleural effusion  No 
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PaO2 =  Arterial  oxygen  tension 
PaCO2  =  Arterial carbon dioxide tension 
PSA  =  Prostate Specific Antigen 
RV =  Residual  Volume 
TLC =  Total  Lung  Capacity 
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